First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591 ...Middle East

MELBOURNE, Australia, Nov. 12, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company's Phase III ProstACT GLOBAL study of its investigational prostate-specific membrane antigen (PSMA)...

Hence then, the article about first patient dosed in phase iii prostact global study of antibody based prostate cancer therapy candidate tlx591 was published today ( Monday 13/11/2023 - 02:44 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591 )

Also on site :

• 8 'Shark Tank' Food Products at Aldi That Are Actually Worth the Hype
• Brendan Sorsby denied request for eligibility reinstatement by NCAA, per report
• Doctor Says Kyle Busch’s Death Was ‘Totally Preventable,’ Lacked 'Protocol'